As China continues to foster favorable conditions for global investment, Kenvue Inc., a leading U.S.-based consumer health company, and Shenzhen Nepstar Medical Co. Ltd., a prominent Chinese drugstore chain, have announced an upgraded strategic cooperation focused on the burgeoning “big health” sector.
The “big health” concept emphasizes a holistic approach that integrates medical care, wellness, disease prevention, and lifestyle management. The partnership aims to innovate products and services while developing an integrated ecosystem for consumers in the health and wellness space.
Gift Arpaporn Samabhandhu, president of Kenvue China, highlighted that the Healthy China 2030 initiative is shifting the public health focus from a “disease-centered” model to a “health-centered” approach. This shift is creating new opportunities for growth in the consumer health industry. The initiative, launched in 2016, aligns health objectives with the United Nations’ sustainable development goals.
Samabhandhu noted that several factors—including an improved policy environment, rising socio-economic levels, heightened public health awareness, an aging population, and evolving consumption patterns among younger demographics—are poised to unlock the consumer health market’s full potential. She emphasized the necessity for companies to adapt their business models to meet evolving consumer health needs and capture market growth opportunities, ultimately driving high-quality development within the sector.
As a first step in their enhanced collaboration, Kenvue and Shenzhen Nepstar recently introduced “Love Teeth Day,” which includes the establishment of oral health centers in Nepstar’s stores. These centers will provide consumers with both oral health education and products.
Kenvue, previously part of Johnson & Johnson’s consumer healthcare division, has a diverse portfolio that includes well-known brands such as Motrin, Tylenol, and Listerine, covering categories from medicines and medical devices to health supplements and cosmetics. The new strategic cooperation not only strengthens their existing collaboration in the over-the-counter (OTC) drug market but also expands into daily care products and the health and beauty sector.
This strategic upgrade reflects both companies’ commitment to enhancing consumer health offerings in China, positioning them well to leverage the significant growth opportunities in the evolving landscape of the consumer health market.